Santhera Pharmaceuticals Holding AG / Santhera to Raise Capital Through Sale of Newly Created Shares . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Liestal, Switzerland, July 31, 2015 - Santhera Pharmaceuticals (SIX: SANN) announces the intent to sell up to 300,000 registered shares of newly created treasury shares (representing 6.03% of the company's total outstanding share capital). The proceeds will be used to finance the commercial launch of Raxone® in Leber's Hereditary Optic Neuropathy (LHON) in Europe.

The shares available-for-sale with a par value of CHF 1.00 will be issued from the Company's conditional capital. The Company has mandated Kepler Chevreux as independent broker to sell the shares to institutional investors and in the open market starting from August 3, 2015.

About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of orphan mitochondrial and neuromuscular diseases. Santhera develops Raxone®/Catena® as treatment for patients with Leber's Hereditary Optic Neuropathy (LHON), Duchenne Muscular Dystrophy (DMD) and primary progressive Multiple Sclerosis (ppMS) and omigapil for Congenital Muscular Dystrophy (CMD), all areas of high unmet medical need. In June 2015, the Committee for Medicinal Products for Human Use (CHMP) recommended granting a marketing authorization in Europe for Raxone® for the treatment of LHON. For further information, please visit the Company's website www.santhera.com:
http://www.santhera.com.

Raxone® and Catena® are trademarks of Santhera Pharmaceuticals.

For further information, contact:
Thomas Meier, PhD, Chief Executive Officer                
Phone +41 61 906 89 64                                              
thomas.meier@santhera.com:
mailto:thomas.meier@santhera.com                                       

Christoph Rentsch, Chief Financial Officer
Phone +41 61 906 89 65
christoph.rentsch@santhera.com :
mailto:christoph.rentsch@santhera.com

US investor contact:                                                   
Hans Vitzthum, LifeSci Advisors, LLC                    
Phone +1 857 272 617                                               
hans@lifesciadvisors.com:
mailto:hans@lifesciadvisors.com                                       


US Public Relations contact:
Deanne Eagle, Planet Communications
Phone +1 917 837 5866
deanne@planetcommunications.nyc:
mailto:deanne@planetcommunications.nyc

Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

# # #

News release Financing:
http://hugin.info/137261/R/1942297/702773.pdf


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Santhera Pharmaceuticals Holding AG via Globenewswire
HUG#1942297

--- End of Message ---

Santhera Pharmaceuticals Holding AG
Hammerstrasse 49 Liestal Switzerland

ISIN: CH0027148649;